We on this thread have often referred to the vast amount of research that is done around the world which supports Benitec's technology and potentially broadens is licensing opportunities. This latest research is a classic example of this this claim. The paper discusses the use of gene therapy to treat AMD. In so doing it completely validates Benitec's AMD program, with in vivo evidence in support of the "proof of concept" for Benitec's program. It now remains to be seen how much of this work we can build on and incorporate into our own pre-clinical studies. Potentially this work could shortcut our development time. I think our team should at least make contact with the author and have a conversation.
In conclusion, these highly promising data clearly demonstrate that viral-encoded RNAi effector molecules can be used for the inhibition of neovascularization and will, in combination with the growing interest of applying DNA- or RNA-based technologies in the clinic, undoubtedly contribute to the development of efficacious long-term gene therapy treatment of intraocular neovascular diseases.
